Ophthalmic Pharmaceutical Compositions and Methods of Making and Using Same

A method for reducing, ameliorating, treating, or controlling a condition of dry eye, the method comprising:

• administering to an affected eye of a patient a composition comprising:
• (a) a first polymer, a viscosity of which changes with a change in a concentration of an electrolyte, when added to said first polymer or a composition comprising said first polymer;
• (b) a second polymer that is different from the first polymer and can modify the viscosity of said first polymer;
• and (c) an oil.

A method for reducing, ameliorating, treating, or controlling ocular hypertension, the method comprising:

• administering to an affected eye of a patient a composition comprising:
• (a) a first polymer, a viscosity of which changes with a change in a concentration of an electrolyte, when added to said first polymer or a composition comprising said first polymer;
• (b) a second polymer that is different from the first polymer and can modify the viscosity of said first polymer;
• (c) an oil;
• (d) a prostaglandin analog dissolved in said oil;
• and (e) water;
• wherein said composition is an oil-in-water emulsion.

A method for enhancing a stability of a prostaglandin analog in an ophthalmic pharmaceutical composition, the method comprising:

• (a) dissolving said prostaglandin analog in an oil;
• (b) adding an aqueous medium to said oil;
• and (c) preparing an oil-in-water emulsion from said oil and said aqueous medium;
• wherein the method results in a degradation of said prostaglandin analog of less than 5 percent of the original concentration thereof after storage at room temperature for 2 weeks.